Dabigatran Etexilate Mesylate

Whakaahuatanga Poto:

Ingoa API Tohutohu Whakatakotoranga US DMF EU DMF CEP
Dabigatran Etexilate Mesylate Te whakakorikori Roto-whare      


Taipitopito Hua

Tohu Hua

WHAKAMAHI HUA

Whakaahuatanga

Ko te Dabigatran etexilate mesylate (BIBR 1048MS) he rongoa a-waha o Dabigatran.Ko te Dabigatran etexilate mesylate he paanga anticoagulant ka whakamahia mo te aukati i te venousthromboembolism me te whiu na te atrial fibrillation.

Papamuri

Whakaahuatanga: IC50 Uara: 4.5nM (Ki);10nM(Thrombin-induced platelet aggregation) [1] Ko te Dabigatran he kaitahuri thrombin tika (DTI) ka taea te huri me te whiriwhiri, kei te haere i te whakawhanaketanga haumanu matatau hei rongoa mo te waha, ko te dabigatran etexilate.i roto i te vitro: Dabigatran maataki me te whakakore i te thrombin tangata (Ki: 4.5 nM) tae atu ki te thrombin-induced platelet aggregation (IC(50): 10 nM), i te kore e whakaatu ana i te awenga aukati ki etahi atu raau taero-whakaongaonga platelet.Thrombin generation in platelet -poor plasma (PPP), i inehia i te mea ko te kaha o te thrombin endogenous (ETP) i aukatihia te kukū-whakaaro (IC(50): 0.56 microM).I whakaatu a Dabigatran i nga paanga anticoagulant e whakawhirinaki ana ki te kukū i roto i nga momo momo i roto i te vitro, ka ruarua te wa o te thromboplastin waahanga (aPTT), te wa prothrombin (PT) me te wa e kii ana i te ecarin (ECT) i roto i te PPP tangata i te kuhanga o te 0.23, 0.83 me te 0.18 microM, ia. 1].in vivo: I whakaroahia e Dabigatran te horopeta aPTT-i muri i te whakahaerenga i roto i nga kiore (0.3, 1 me te 3 mg / kg) me nga makimaki rhesus (0.15, 0.3 me te 0.6 mg / kg).I kitea nga paanga anticoagulant inenga-a-waa me te dabigatran etexilate i tukuna ma te waha ki nga kiore mohio (10, 20 me te 50 mg/kg) me nga makimaki rhesus (1, 2.5, 5 mg/kg ranei), me nga paanga teitei ka kitea i waenga i te 30 me te 120 min i muri i te whakahaerenga, ia [1].Ko nga turoro e rongoahia ana e te dabigatran etexilate he iti ake nga whiu ischemic (3.74 dabigatran etexilate vs 3.97 warfarin) me te iti ake o te whakakotahitanga o te toto toto me nga whiu haemorrhagic (0.43 dabigatran etexilate vs 0.99 warfarin) mo ia 100 tau manawanui.Te whakamatautau haumanu: He Aromatawai o te Pharmacokinetics me te Pharmacodynamics o Oral Dabigatran Etexilate i roto i nga turoro Hemodialysis.Wāhanga1

Rokiroki

Paura

-20°C

3 tau
 

4°C

2 tau
I te whakarewa

-80°C

6 marama
 

-20°C

1 marama

Whakamatautau Haumanu

Nama NCT Kaitautoko Tikanga Rā Tīmata

Wāhanga

NCT02170792 Boehringer Ingelheim Hauora Hui-tanguru 2001

Wāhanga 1

NCT02170974 Boehringer Ingelheim Hauora Hōngongoi 2004

Wāhanga 1

NCT02170831 Boehringer Ingelheim Hauora Haratua 1999

Wāhanga 1

NCT02170805 Boehringer Ingelheim Hauora Paenga-whāwhā 2001

Wāhanga 1

NCT02170610 Boehringer Ingelheim Hauora Poutū-te-rangi 2002

Wāhanga 1

NCT02170909 Boehringer Ingelheim Hauora Hakihea 2004

Wāhanga 1

NCT02171000 Boehringer Ingelheim Hauora Paenga-whāwhā 2005

Wāhanga 1

NCT02170844 Boehringer Ingelheim Hauora Pipiri 2004

Wāhanga 1

NCT02170584 Boehringer Ingelheim Hauora Hanuere 2001

Wāhanga 1

NCT02170935 Boehringer Ingelheim Ko te Thromboembolism Venous Paenga-whāwhā 2002

Wāhanga 2

NCT02170636 Boehringer Ingelheim Hauora Hanuere 2002

Wāhanga 1

NCT02170766 Boehringer Ingelheim Hauora Oketopa 2000

Wāhanga 1

NCT02171442 Boehringer Ingelheim Hauora Paenga-whāwhā 2002

Wāhanga 1

NCT02170896 Boehringer Ingelheim Hauora Oketopa 2001

Wāhanga 1

NCT02173730 Boehringer Ingelheim Hauora Noema 2002

Wāhanga 1

NCT02170623 Boehringer Ingelheim Hauora Hui-tanguru 2002

Wāhanga 1

NCT02170116 Boehringer Ingelheim Hauora Noema 1998

Wāhanga 1

NCT02170597 Boehringer Ingelheim Hauora Akuhata 2003

Wāhanga 1

NCT01225822 Boehringer Ingelheim Ko te Thromboembolism Venous Noema 2002

Wāhanga 2

NCT02170701 Boehringer Ingelheim Ko te Thromboembolism Venous Oketopa 2000

Wāhanga 2

NCT02170740 Boehringer Ingelheim Hauora Noema 1999

Wāhanga 1

NCT02170922 Boehringer Ingelheim Hauora Hōngongoi 1999

Wāhanga 1

Hanganga matū

Dabigatran Etexilate Mesylate

Tiwhikete

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

TE WHAKAMAHI KOI

Quality management1

Tono18Ko nga kaupapa Aromātai Tauritenga Kounga kua whakaaetia4, a6kei te whakamanahia nga kaupapa.

Quality management2

Ko te punaha whakahaere kounga teitei o te ao kua whakatakoto he turanga pakari mo nga hoko.

Quality management3

Ko te tirotiro i te kounga ka haere i roto i te huringa ora katoa o te hua ki te whakarite i te kounga me te hua rongoa.

Quality management4

Ko te roopu Whakahaere Whakahaere Ngaio e tautoko ana i nga hiahia kounga i te wa o te tono me te rehitatanga.

WHAKAMAHI WHAKATANGA

cpf5
cpf6

Korea Countec Pounamu Whakapai Raina

cpf7
cpf8

Taiwan CVC Pounamu Packaging Raina

cpf9
cpf10

Itari CAM Board Packaging Raina

cpf11

Miihini Whakakii Fette Tiamana

cpf12

Hapanihi Viswill Tablet Detector

cpf14-1

Rūma Whakahaere DCS

HOANI

Te mahi tahi o te ao
International cooperation
Te mahi tahi a-whare
Domestic cooperation

  • Tōmua:
  • Panuku:

  • Tuhia to korero ki konei ka tukuna mai ki a matou